PARIS (Reuters) - Sanofi aims to build on its diabetes portfolio, which has so far relied on blockbuster insulin Lantus, with a wider range of treatments that could address not just the disease but also its numerous complications, its research head said on Thursday.
Source: http://feeds.reuters.com/~r/reuters/healthNews/~3/5PUol0fFhiU/us-sanofi-diabetes-idUSBRE84U0NU20120531
education programs in california phlebotomy training indianapolis how long is a phlebotomy course
No comments:
Post a Comment